TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16442264
Drug: Combined technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined technique using nitrous oxide/oxygen and intravenous Midazolam
Study: 9431825
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (ethanol administered by i.v. infusion)
Study: 29729702
Drug: Kidney Flaccidity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney Flaccidity Compound (KFC) for 1.5 months
Study: 29729702
Drug: Kidney Flaccidity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney Flaccidity Compound (KFC) for 3 months
Study: 29729702
Drug: Kidney Flaccidity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney Flaccidity Compound (KFC)
Study: 23885616
Drug: Elongated needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elongated needle treatment
Study: 20629511
Drug: Genomic approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic approaches to treatment response including detection of gene rearrangements, DNA copy-number aberrations, single-nucleotide polymorphisms, epigenetic changes, and differential gene-expression patterns.
Study: 20629511
Drug: Genomic approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic approaches to treatment response
Study: 1376839
Drug: Modified-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release formulation of isradipine (Im) at 5 mg once daily
Study: 1376839
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of isradipine (Is) at 2.5 mg twice daily
Study: 1376839
Drug: Modified-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release formulation of isradipine (Im)
Study: 1376839
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of isradipine (Is)
Study: 2864027
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control treatment
Study: 31726876
Drug: G-estimation method
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-estimation method for treatment on the outcome (physical activity)
Study: 31726876
Drug: G-estimation method
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-estimation method
Study: 28793896
Drug: MEDI8968 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8968 300 mg subcutaneously every 4 weeks (600 mg intravenous loading dose) for 52 weeks
Study: 28793896
Drug: MEDI8968 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8968 300 mg
Study: 21426232
Drug: Cinnarizine 25
Normalized name: cinnarizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 25 mg every 12 hours for 6 months (n=50)
Study: 18279183
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus sub-antimicrobial dose of doxycycline
Study: 17262127
Drug: Carisolv gel
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisolv gel + SRP
Study: 17262127
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel + SRP
Study: 12527536
Drug: Functional adaptation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional adaptation skills training (FAST) group therapy program (24 sessions)
Study: 10770538
Drug: Zidovudine (ZDV;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day)
Study: 10770538
Drug: Zidovudine (ZDV;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day) plus indinavir (IND; 800 mg q8h)
Study: 26902950
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 3-month formulation (PP3M)
Study: 23953322
Drug: Ketamine (0.227
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.227 mg/kg for ED50; 0.283 mg/kg for ED95)
Study: 20560900
Drug: Sertindole 12
Normalized name: sertindole 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 12 mg
Study: 20560900
Drug: Sertindole 20
Normalized name: sertindole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 20 mg
Study: 20560900
Drug: Sertindole 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 24 mg
Study: 20560900
Drug: Haloperidol 8
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 8 mg
Study: 20560900
Drug: Haloperidol 16
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 16 mg
Study: 17869975
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 mg/d after a 70-mg loading dose)
Study: 17869975
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.6-1.0 mg/kg per day)
Study: 15491237
Drug: ACASI survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACASI survey self‐administered through an Internet browser using a touchscreen
Study: 11505696
Drug: Soft type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft type margarine (30 g total per day, 15 g twice a day)
Study: 11505696
Drug: Butter (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter (30 g total per day, 15 g twice a day)
Study: 9752402
Drug: Laparoscopic repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic repair (L group)
Study: 31650328
Drug: High-fibre intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fibre intake (39 g/day)
Study: 31650328
Drug: Low-fibre intake
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fibre intake (18 g/day)
Study: 23862170
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy (subgroup)
Study: 23862170
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (subgroup)
Study: 17934721
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of nicotine delivered via nasal spray
Study: 17071438
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 2 g/day
Study: 17071438
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg twice-daily
Study: 10740110
Drug: Fenspiride (Pneumorel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride (Pneumorel 80mg) plus antibiotic therapy (Amoxicillin 500mg plus clavulanic acid 125, 3 tablets/day)
Study: 10740110
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus antibiotic therapy (Amoxicillin 500mg plus clavulanic acid 125, 3 tablets/day)
Study: 9200635
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate hydrochloride (LAAM) high-dose condition (100/100/140 mg)
Study: 9200635
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate hydrochloride (LAAM) medium-dose condition (50/50/70 mg)
Study: 9200635
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate hydrochloride (LAAM) low-dose condition (25/25/35 mg)
Study: 8261875
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of methadone
Study: 9283506
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of methadone
Study: 8261875
Drug: methadone-free treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: methadone-free treatment
Study: 31215440
Drug: QbTest added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QbTest added to medication management
Study: 29843676
Drug: Intake of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of typical antipsychotics
Study: 25312554
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of insulin (group 1)
Study: 25312554
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of insulin glargine (group 2)
Study: 25312554
Drug: Insulin dosage
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dosage during 6-month follow-up
Study: 8089358
Drug: Fibrel implant
Normalized name: triticum (wheat fibre)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrel implant
Study: 4603999
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg prednisone, daily for a week
Study: 22855914
Drug: UHV-HPMC (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UHV-HPMC (4 g)
Study: 22855914
Drug: Psyllium fiber
Normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium fiber (4 g)
Study: 18331577
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (NTG)
Study: 12907528
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation plus inhaled ipratropium bromide
Study: 27527344
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion threshold (eligible for transfusion if post-operative haemoglobin < 7.5 g/dl)
Study: 27527344
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion threshold (eligible for transfusion immediately after randomisation if post-operative haemoglobin < 9 g/dl)
Study: 17030104
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) - estrogen plus progesterone
Study: 15793193
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) at baseline and after approximately 2 years
Study: 15793193
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in insulin sensitivity related to weight change
Study: 15793193
Drug: Fasting glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose, insulin, and C-peptide
Study: 7792438
Drug: rhDNase 0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase 0.6, 2.5, 10 mg
Study: 7792438
Drug: rhDNase 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase 2.5 mg, once or twice daily
Study: 2235167
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (including crossover)
Study: 369049
Drug: Supervised oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised oral hygiene action with amine fluoride-containing agents Silca and Elmex fluid
Study: 25596660
Drug: Chemoradiotherapy (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (three cycles of cisplatin 100 mg/m(2))
Study: 25596660
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus chemoradiotherapy (three cycles of intravenous panitumumab 9.0 mg/kg every 3 weeks plus cisplatin 75 mg/m(2))
Study: 23131530
Drug: Hydrochlorothiazide 1
Normalized name: hydrochlorothiazide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 1 mg/kg/day as morning dose
Study: 22379918
Drug: FFP 5423+417
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFP 5423+417 ml and crystalloids 11048+458 ml (1:2 ratio)
Study: 22379918
Drug: FFP 6882+943
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFP 6882+943 ml and crystalloids 6690+882 ml (1:1 ratio)
Study: 22379918
Drug: FFP 7532+1196
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFP 7532+1196 ml and crystalloids 3720+629 ml (2:1 ratio)
Study: 7514771
Drug: Morphine or
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine or Heroin (specific dosage not mentioned)
Study: 30928252
Drug: ICRS followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICRS followed by CXL (concurrent)
Study: 30928252
Drug: ICRS followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICRS followed by CXL 3 months later (sequential)
Study: 27798042
Drug: 6-month lifestyle
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month lifestyle intervention preceding infertility treatment
Study: 17982321
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (EGb 761, 300 mg/day)
Study: 11073288
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral dose of imiquimod after fasting
Study: 11073288
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral dose of imiquimod after a standardized, high fat meal
Study: 11073288
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg subcutaneous dose of imiquimod
Study: 1319110
Drug: Psyllium-enriched cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium-enriched cereal (114 g/d)
Study: 2984980
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered enviroxime
Study: 3694540
Drug: Lorazepam (LZ)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (LZ) 1.5‐9.0 mg
Study: 3694540
Drug: Meprobamate (MEP)
Normalized name: Meprobamate
DrugBank: Meprobamate (DB00371)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meprobamate (MEP) 600‐3600 mg
Study: 30972904
Drug: Knutson's formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knutson's formula (povidone-iodine and sugar solution)
Study: 30972904
Drug: Traditional topical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional topical drugs
Study: 25585890
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy at a dose of 54 Gy in 30 fractions
Study: 16505084
Drug: Sodium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium supplementation (620 mg table salt)
Study: 16505084
Drug: Placebo (596
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (596 mg starch)
Study: 12740158
Drug: HPS cream
Normalized name: capsaicin Topical Cream [Capzasin-HP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPS cream (Crystacide 1%) applied topically twice daily for 8 weeks
Study: 12740158
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide gel (PanOxyl gel 4%) applied topically twice daily for 8 weeks
Study: 12903500
Drug: Oral furtulon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral furtulon therapy
Study: 9313274
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three opioids (morphine, hydromorphone, sufentanil)
Study: 7691253
Drug: Intensive weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive weekly chemotherapy (VAPEC-B) alone
Study: 7691253
Drug: Intensive weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive weekly chemotherapy (VAPEC-B) with granulocyte colony-stimulating factor (G-CSF)
Study: 7691253
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone or chemotherapy with G-CSF
Study: 3536397
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISDN
Study: 3536397
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ISDN
Study: 3536397
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ISDN
Study: 3536397
Drug: ISDN (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (all doses)
Study: 30318772
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment in patients with FCGR2A H/H genotype (n=165, 28%)
Study: 30318772
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment in patients with FCGR2A R/- genotype (n=427, 72%)
Study: 30318772
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment in patients with FCGR2A H/R genotype
Study: 30318772
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment in patients with FCGR2A H/H + FCGR3A F/F genotype
Study: 24652107
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg
Study: 20034947
Drug: Triple dye
Normalized name: Triple Dye
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dye plus rubbing alcohol (isopropyl alcohol) twice daily
Study: 16632346
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by craniospinal RT (35 Gy in 21 fractions + boost of 20 Gy in 12 fractions)
Study: 29995181
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and motivation instructions in oral health and plaque control
Study: 29231293
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at Zusanli (ST 36) and Zhigou (TE 6), 30 min for each treatment, once a day for 5 days.
Study: 29231293
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment including intensive care, gastrointestinal decompression, fasting, blood capacity supplement, acid suppression treatment, internal environment maintenance, infection prevention, inhibition of pancreatic exocrine secretion.
Study: 22078660
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400mg daily) + Calcium (1200mg) + Vitamin D(3) (1000 IU)
Study: 15308515
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 3 mg/kg, three i.v. infusions on weeks 0, 2, and 6
Study: 15308515
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 1 g, single i.v. infusion
Study: 11468195
Drug: Cerivastatin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.15 mg/d for 3 days)
Study: 2454980
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 1 U/ml bleomycin sulfate
Study: 2454980
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution injection (control)
Study: 27690687
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg daily for 4 weeks, then 1500 mg daily for 8 weeks
Study: 27690687
Drug: Megestrol 40
Normalized name: megestrol 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol 40 mg daily for 12 weeks
Study: 25060103
Drug: Forgiveness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forgiveness therapy (conducted once a week for 12 weeks)
Study: 22057729
Drug: Micronized aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized aspirin 500 mg
Study: 22057729
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin 500 mg tablets
Study: 12566892
Drug: Sildenafil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (200 mg)
Study: 9640412
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (Genotropin) 0.25 IU/Kg/week (0.125 IU/kg/week for the first four weeks)
Study: 9404870
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of creatine monohydrate per day for 5 consecutive days
Study: 7059561
Drug: Chilean mixed
Normalized name: Chilean hazelnut oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chilean mixed diet at protein levels of 0.40, 0.55, and 0.70 g/kg body-weight per day
Study: 7059561
Drug: Egg reference
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg reference diet providing 0.30, 0.45, and 0.60 g protein/kg per day
Study: 28689602
Drug: Moisturizing gel
Normalized name: MOISTURIZING GEL
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing gel containing malva nut polysaccharide
Study: 24030571
Drug: Pre-filled syringe
Normalized name: Eylea Pre-filled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe formulation of canakinumab
Study: 24030571
Drug: Reconstituted lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted lyophilized formulation of canakinumab
Study: 17001467
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine (L-alanyl-L-glutamine 200mg/ml) for 20h at a rate of 0.125ml/kg/h
Study: 9591517
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day tolcapone